According to a Wall Street Journal report, the U.S.-based drugmaker Pfizer (PFE) could soon be taking its impressive mRNA technology to the wider world of medicine. Teaming up with German drug developer, BioNTech (BTNX), Pfizer was able to deliver the first approved vaccine to market, to fight the COVID-19 virus, using its mRNA technology, which
Sure, it has slightly lower efficacy than the Pfizer (PFE) and Moderna (MRNA) vaccines, but the Johnson & Johnson (JNJ) shot has the incredible advantage of not requiring a second shot. With America so torn on the merits and health risks of the two-shot vaccine, there are lots of people who would like the single-shot solution.
It’s no secret that the world, American especially, is split on the merits of the COVID-19 vaccine. While the number is somewhat decreasing, whether politically driven, a genuine question of necessity, or concerns over adverse side effects, you don’t have to go far to find people with no immediate plans of signing up for the
While AstraZeneca’s (AZN) COVID-19 vaccine still awaits approval for use in the U.S., the drugmaker is still cashing in on the progress of vaccines here in the states. Nicknamed the Oxford-vaccine, AstraZeneca’s vaccine, which has only gained approval in Europe, trails drugmakers Pfizer (PFE), BioNTech (BNTX) and Moderna (MRNA) in the U.S., yet still managed
It’s been a wild 12 months for Moderna (MRNA), the drugmaker who’s been smack dab in the center of the COVID-19 vaccine conversation since last spring. Shortly after Pfizer (PFE) and BioNTech (BNTX) debuted their vaccine in early December, Moderna came to market a week later, and still remains one of the only two vaccines
On paper, there’s a lot to like about the Johnson & Johnson (JNJ) COVID-19 vaccine. Today, the Food and Drug Administration said it comes with no unexpected safety concerns, and unlike Pfizer (PFE) or Moderna (MRNA) vaccine, J&J’s does not require the use of special refrigeration. But above all, it only requires one shot, rather
We may soon have a third major COVID-19 vaccine on the way, as Novavax (NVAX) seeks to join Pfizer and Moderna for approval and widespread distribution. Novavax announced today that its experimental vaccine would enter phase three study in the U.S. Its vaccine is already in phase three in the U.K. The U.S. federal government
With countless polls across the country from a variety of sources, including this one from the Associated Press, reporting that roughly half of all Americans are still very much on the fence about getting the COVID-19 vaccine, the U.S. Government continues to march forward. Today, it was announced that Pfizer (PFE) and its drugmaking partner BioNTech
Take your pick… there’s more than enough reasons to call this year historic. While most are worth forgetting, looking back on the urgency and efficiency at which drugmakers around the world developed and distributed an approved COVID-19 is impressive. With all hands on deck, a process that usually takes up to 5-10 years was accomplished
Since the pandemic reared its ugly head earlier this year, the names Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), AstraZeneca (AZN) and more all became household names and the fixture of portfolios everywhere. While it’s fair that since these names headlined much of the news around Operation Warp Speed, leading the nation’s race to develop an
With the novel coronavirus stealing the show this year, innovation in the biotech space has been just… a little overshadowed by the race to develop a worldwide vaccine. Considering the pandemic has taken more than 1.6 million lives across the globe, the “all-hands-on-deck” approach is certainly understandable. But just because the vaccine race has taken
There has been much more than enough news around the race to develop an effective COVID-19 vaccine this year to make your head spin. We’ve all seen the names. Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), AstraZeneca (AZN), Johnson & Johnson (JNJ) and a host of others… they’ve all been claiming trial results showing 90%, 94%,
The race to produce a bonafide, FDA-approved COVID-19 vaccine has been a tightly contested race between drugmakers across the world who all want to be the first to market. The competition has been great, as it’s led to an approved vaccine in a matter of 10 months, rather than the usual 5-10 years it would
